Primary information |
---|
ID | 16188 |
Therapeutic ID | Th1701 |
Protein Name | IGN301 |
Sequence | NA
|
Molecular Weight | NA |
Chemical Formula | NA |
Isoelectric Point | NA |
Hydrophobicity | NA |
Melting point | NA |
Half-life | NA |
Description | IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers). |
Indication/Disease | Investigated for use/treatment in cancer/tumors (unspecified). |
Pharmacodynamics | NA |
Mechanism of Action | IGN301 is based on an anti-idiotype antibody designed to trigger an immune response to Lewis Y, a carbohydrate molecule frequently overexpressed in tumor cells of epithelial origin such as lung, colon, breast, prostate or ovarian cancer. |
Toxicity | NA |
Metabolism | NA |
Absorption | NA |
| NA |
Clearance | NA |
Categories | NA |
Patents Number | NA |
Date of Issue | NA |
Date of Expiry | NA |
Drug Interaction | NA |
Target | NA |
Brand Name | NA |
Company | NA |
Brand Description | NA |
Prescribed For | NA |
Chemical Name | NA |
Formulation | NA |
Physical Appearance | NA |
Route of Administration | NA |
Recommended Dosage | NA |
Contraindication | NA |
Side Effects | NA |
Useful Link 1 | Link |
Useful Link 2 | NA |
Remarks | NA |